Skip to search formSkip to main contentSkip to account menu

1 ML secukinumab 150 MG/ML Prefilled Syringe

Known as: secukinumab 150 MG in 1 ML Prefilled Syringe, SECUKINUMAB 150MG/ML INJ 1 ML SYR, SECUKINUMAB 150MG/ML INJ,SYR,1ML [VA Product] 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

1 ML secukinumab 150 MG/ML Prefilled Syringe [Cosentyx]

Broader (1)

Immunosuppressive Agents
Prefilled Syringesecukinumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
FRI0402 SECUKINUMAB FOR AXIAL SPONDYLOARTHRITIS: DRUG SURVIVAL IN REAL-WORLD SETTING AND RESPONSE FACTORS
Background IL-17 inhibition has been proved effective in patients with ankylosing spondylitis (AS) in clinical trials and it has… 
2018
2018
PMS31 - SECUKINUMAB AS A MORE EEFICIENT ALTERNATIVE FOR ANKYLOSING SPONDYLITIS TREATMENT: A COST PER RESPONDER ANALYSIS FROM KOREAN PERSPECTIVE
2018
2018
THU0319 Overall safety of 7-week secukinumab exposure during pregnancy in women with psoriatic arthritis
Background Psoriatic arthritis (PsA) often affects women of reproductive age. Secukinumab (SEC), a monoclonal antibody against… 
2018
2018
PMS42 - SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE
2018
2018
PMS29 - SECUKINUMAB VERSUS ADALIMUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AMONG 52 WEEKS FROM A TUNISIAN PERSPECTIVE.
Review
2017
Review
2017
Psoriasis-Arthritis und Spondyloarthritiden: Treat-to-target, Tight control und neue Therapien
Was ist neu? Von der Pathophysiologie zu neuen Therapietargets Die Interaktion zwischen Genetik, dem Mikrobiom des Darms und… 
2017
2017
Aktueller Stand der Therapie der axialen Spondyloarthritis mit biologischen DMARDs
Zusammenfassung Innerhalb der vergangenen Jahre konnten eindeutige Ziele für die Therapie der axSpA definiert werden. Einerseits… 
2017
2017
Nicht alle Patienten erwarten Antibiotika
Die aktuell vorgestellten Ergebnisse der multizentrischen, doppelt verblindeten Anschlussstudie zur Phase-III-Studie SCULPTURE… 
Review
2016
Review
2016
THU0437 Secukinumab for The Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Licensed Biologics and Apremilast from A Network Meta-Analysis
Background Secukinumab (SEC) is approved for the treatment of active PsA in adults who have responded inadequately to DMARD… 
2015
2015
THU0421 Secukinumab is Effective in Reducing Dactylitis and Enthesitis Using Multiple Measures in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo…
Background Dactylitis and enthesitis are common disabling manifestations of psoriatic arthritis (PsA) that have been reported… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)